Oncolytics Biotech (ONCY) 0.51 $ONCY
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 11:40AM CST
Oncolytics Biotech Inc.'s (ONCY) lead candidate, Reolysin, has been granted orphan drug designation by the FDA for the treatment of ovarian cancer.
BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), BMRN: 100.76 (+1.98)
Oncolytics' Reolysin an Orphan Drug for ovarian cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:34AM CST
ONCY: 0.51 (+0.02)
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer
PR Newswire - Wed Feb 11, 5:30AM CST
Oncolytics Biotech® Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of ovarian cancer.
ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 229.49 (+1.87), BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), ARRY: 8.05 (+0.08)
Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients
PR Newswire - Mon Feb 09, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA" for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN® can infect a variety of brain tumors when delivered intravenously.
ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and Ovarian Cancers
CNW Group - Mon Dec 22, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA" for REOLYSIN(®) for the treatment of pancreatic and ovarian cancers.
ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Osteosarcoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjklc9/osteosarcoma) has announced the addition of the "Osteosarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Oncolytics Biotech Inc. - Med Discovery SA - Aileron Therapeutics, Inc. - Merrimack Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Sutro Biopharma, Inc. - Eleison Pharmaceuticals, Inc. - Apoplogic Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/kj...teosarcoma
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), BLCM: 20.00 (-0.81), GSK: 47.94 (+1.99)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Ewing Sarcoma - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jf65/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - Amgen Inc. - AstraZeneca PLC - Daiichi Sankyo Company, Limited - Sigma-Tau S.p.A. - Oncolytics Biotech Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - EntreChem, S.L. For more information visit http://www.researchandmarkets.com/research/l4...ing_sarcom
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/kspvsg/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Genentech, Inc. - MedImmune, LLC - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Merck KGaA - Oncolytics Biotech Inc. - Panacea Biotec Limited - PCI Biotech AS - Glycotope GmbH - VentiRx Pharmaceuticals, Inc. - Immunovative Therapies, Ltd. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/ks...rrent_head
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), NVS: 102.20 (-0.17)
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® and Checkpoint Inhibitor Combination Preclinical Data at AACR Tumor Immunology and Immunotherapy Conference
CNW Group - Thu Dec 04, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC) (NASDAQ:ONCY) today announced a poster presentation by the Company's research collaborators, Vile et al., titled "Combination Therapy with Reovirus and PD-1 Blockade Effectively Establishes Tumour Control Via Innate and Adaptive Immune Responses" was made at the AACR Tumor Immunology and Immunotherapy Conference being held from December 1(st) through 4(th) in Orlando, Florida.
ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Oncolytics Files for Orphan Drug Designation for Reolysin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 3:30PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted applications to the FDA seeking orphan drug designation for Reolysin.
ACT: 285.37 (+3.71), ONCY: 0.51 (+0.02), AMGN: 153.48 (+0.30), AMAG: 41.49 (+0.23)
Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers
PR Newswire - Tue Dec 02, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics" (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA" for REOLYSIN® for the treatment of pancreatic and ovarian cancers.
ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Media Advisory - Oncolytics Biotech® Inc. to Participate in the Stifel 2014 Healthcare Conference
PR Newswire - Tue Nov 18, 5:30AM CST
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Stifel 2014 Healthcare Conference in a session on Wednesday November 19th, 2014 at 8:35 a.m. ET. The conference takes place on November 18th and 19th at the New York Palace, in New York, NY.
ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Seeking Alpha's Biotech Weekly: Crush-Proof Pfizer, Achillion's HCV Crusher, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 13, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), XON: 39.30 (+1.05), CTIC: 2.23 (-0.02), PFNX: 12.45 (+0.29), JNJ: 99.62 (+1.18), ANTM: 141.05 (-0.95), NVAX: 8.80 (+0.40), SHPG: 239.82 (+6.11), ABBV: 58.05 (+1.00), TBPH: 18.51 (+0.28), SNY: 49.42 (+0.82), ALQA: 6.14 (+0.09), REGN: 402.40 (+0.66), ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), SLXP: 152.35 (+3.17), EPRS: 7.67 (+0.67), AMGN: 153.48 (+0.30), NKTR: 13.54 (-0.14), ZTS: 45.46 (-0.33), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), GERN: 3.03 (unch)
Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 11:40AM CST
Oncolytics Biotech Inc.'s (ONCY) lead candidate, Reolysin, has been granted orphan drug designation by the FDA for the treatment of ovarian cancer.
BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), BMRN: 100.76 (+1.98)
Oncolytics' Reolysin an Orphan Drug for ovarian cancer
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 9:34AM CST
ONCY: 0.51 (+0.02)
Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Ovarian Cancer
PR Newswire - Wed Feb 11, 5:30AM CST
Oncolytics Biotech® Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of ovarian cancer. ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Oncolytics Seeks Orphan Drug Status for Reolysin in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:59PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients.
AGN: 229.49 (+1.87), BIIB: 391.66 (-0.45), ONCY: 0.51 (+0.02), ARRY: 8.05 (+0.08)
Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for High Grade Gliomas in Pediatric Patients
PR Newswire - Mon Feb 09, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY) today announced that it has submitted an application for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA" for REOLYSIN® for the treatment of high grade gliomas (HGG) in pediatric patients. Oncolytics has conducted three previous clinical studies in brain cancers including gliomas, and has found that REOLYSIN® can infect a variety of brain tumors when delivered intravenously. ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and Ovarian Cancers
CNW Group - Mon Dec 22, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Designation to the European Medicines Agency ("EMA" for REOLYSIN(®) for the treatment of pancreatic and ovarian cancers. ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Osteosarcoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/kjklc9/osteosarcoma) has announced the addition of the "Osteosarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Oncolytics Biotech Inc. - Med Discovery SA - Aileron Therapeutics, Inc. - Merrimack Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Sutro Biopharma, Inc. - Eleison Pharmaceuticals, Inc. - Apoplogic Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/kj...teosarcoma
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), BLCM: 20.00 (-0.81), GSK: 47.94 (+1.99)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Ewing Sarcoma - Pipeline Review, H1 2014
M2 - Mon Dec 15, 3:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jf65/ewing_sarcoma) has announced the addition of the "Ewing Sarcoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Ewing Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ewing Sarcoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Ewing Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Ewing Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shionogi & Co., Ltd. - Amgen Inc. - AstraZeneca PLC - Daiichi Sankyo Company, Limited - Sigma-Tau S.p.A. - Oncolytics Biotech Inc. - Merrimack Pharmaceuticals, Inc. - Pharma Mar, S.A. - EntreChem, S.L. For more information visit http://www.researchandmarkets.com/research/l4...ing_sarcom
MACK: 10.22 (+0.40), ONCY: 0.51 (+0.02), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/kspvsg/recurrent_head) has announced the addition of the "Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Genentech, Inc. - MedImmune, LLC - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Merck KGaA - Oncolytics Biotech Inc. - Panacea Biotec Limited - PCI Biotech AS - Glycotope GmbH - VentiRx Pharmaceuticals, Inc. - Immunovative Therapies, Ltd. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/ks...rrent_head
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), NVS: 102.20 (-0.17)
Oncolytics Biotech® Inc. Collaborators Present REOLYSIN® and Checkpoint Inhibitor Combination Preclinical Data at AACR Tumor Immunology and Immunotherapy Conference
CNW Group - Thu Dec 04, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC) (NASDAQ:ONCY) today announced a poster presentation by the Company's research collaborators, Vile et al., titled "Combination Therapy with Reovirus and PD-1 Blockade Effectively Establishes Tumour Control Via Innate and Adaptive Immune Responses" was made at the AACR Tumor Immunology and Immunotherapy Conference being held from December 1(st) through 4(th) in Orlando, Florida. ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Oncolytics Files for Orphan Drug Designation for Reolysin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 03, 3:30PM CST
Oncolytics Biotech Inc. (ONCY) announced that it has submitted applications to the FDA seeking orphan drug designation for Reolysin.
ACT: 285.37 (+3.71), ONCY: 0.51 (+0.02), AMGN: 153.48 (+0.30), AMAG: 41.49 (+0.23)
Oncolytics Biotech® Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers
PR Newswire - Tue Dec 02, 5:30AM CST
Oncolytics Biotech Inc. ("Oncolytics"
(TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Drug Designation to the U.S. Food and Drug Administration ("FDA" for REOLYSIN® for the treatment of pancreatic and ovarian cancers. ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
Media Advisory - Oncolytics Biotech® Inc. to Participate in the Stifel 2014 Healthcare Conference
PR Newswire - Tue Nov 18, 5:30AM CST
Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate in the Stifel 2014 Healthcare Conference in a session on Wednesday November 19th, 2014 at 8:35 a.m. ET. The conference takes place on November 18th and 19th at the New York Palace, in New York, NY.
ONCY: 0.51 (+0.02), ONC.TO: 0.63 (+0.01)
